Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy

Future OncologyVol. 17, No. 7 EditorialImmune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapyAlessandro Rizzo‡, Angela Dalia Ricci‡ & Giovanni BrandiAlessandro Rizzo‡ *Author for correspondence: Tel.: +39 051 214 4078; E-mail Address: rizzo.alessandro179@gmail.comhttps://orcid.org/0000-0002-5257-8678Department of Experimental, Diagnostic & Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, 40138, Italy, Angela Dalia Ricci‡Department of Experimental, Diagnostic & Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, 40138, Italy & Giovanni BrandiDepartment of Experimental, Diagnostic & Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, 40138, ItalyPublished Online:29 Jan 2021https://doi.org/10.2217/fon-2020-0986AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: atezolizumabbevacizumabHCChepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapyReferences1. Chen LT, Martinelli E, Cheng AL et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann. Oncol. 31(3), 334–351 (2020).Crossref, Medline, Google Scholar2. Rizzo A, Ricci AD, Brandi G. Adjuvant systemic treatment in hepatocellular carcinoma: tempted to do something, rather than nothing. Future Oncol. 16(32), 2587–2589 (2020).Link, CAS, Google Scholar3. Llovet JM, Ricci S, Mazzaferro V et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).Crossref, Medline, CAS, Google Scholar4. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25–34 (2009).Crossref, Medline, CAS, Google Scholar5. Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet 391(10126), 1163–1173 (2018).Crossref, Medline, CAS, Google Scholar6. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 391(10127), 1301–1304 (2018).Crossref, Medline, Google Scholar7. El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet 389(10088), 2492–2502 (2017).Crossref, Medline, CAS, Google Scholar8. Edeline J, Yau T, Park JW et al. CheckMate 459: health-related quality of life (HRQoL) in a randomized, multicenter Phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). J. Clin. Oncol. 38(Suppl. 4), 483–483 (2020).Crossref, Google Scholar9. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15(5), 325–340 (2018).Crossref, Medline, CAS, Google Scholar10. Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15(5), 310–324 (2018).Crossref, Medline, CAS, Google Scholar11. Hack SP, Spahn J, Chen M et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 16(15), 975–989 (2020).Link, CAS, Google Scholar12. Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin. Cancer Biol. 52(Pt 2), 117–124 (2018).Crossref, Medline, CAS, Google Scholar13. Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382(20), 1894–1905 (2020).Crossref, Medline, CAS, Google Scholar14. Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J. Hepatol. 72(2), 342–352 (2020).Crossref, Medline, CAS, Google Scholar15. Zhu AX, Finn RS, Ikeda M et al. A Phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). J. Clin. Oncol. 38, Abstract 4519 (2020).Crossref, Google Scholar16. Kelley RK, Oliver JW, Hazra S et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncol. 16(21), 1525–1536 (2020).Link, CAS, Google Scholar17. Kelley RK, Sangro B, Harris WP et al. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). J. Clin. Oncol. 38(Suppl. 15), 4508–4508 (2020).Crossref, Google Scholar18. Lim H, Ramjeesingh R, Liu D et al. Optimizing survival by changing the landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review. J. Natl Cancer Inst. 113(2), 123–136 (2020).Crossref, Google ScholarFiguresReferencesRelatedDetailsCited ByThe Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC1 March 2023 | Journal of Hepatocellular Carcinoma, Vol. Volume 10Arterial chemoembolization for patients with hepatocellular carcinoma and elevated lactate dehydrogenase is associated with low survival: a cohort study16 June 2022 | Infectious Agents and Cancer, Vol. 17, No. 1Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy26 September 2022 | International Journal of Molecular Sciences, Vol. 23, No. 19Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma29 September 2022 | Frontiers in Genetics, Vol. 13Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report17 August 2022 | Frontiers in Immunology, Vol. 13The potential mechanism of Chebulae Fructus in the treatment of hepatocellular carcinoma on the basis of network pharmacologyAnnals of Hepatology, Vol. 27, No. 4Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects13 December 2021 | Expert Opinion on Investigational Drugs, Vol. 31, No. 6Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond25 November 2021 | Expert Opinion on Investigational Drugs, Vol. 31, No. 6NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and MetastasisOxidative Medicine and Cellular Longevity, Vol. 2022Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world studyHeliyon, Vol. 8, No. 6Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?Alessandro Rizzo23 February 2022 | Future Oncology, Vol. 18, No. 14The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals23 July 2021 | Journal of Cancer Research and Clinical Oncology, Vol. 148, No. 5Hypofractionated Radiotherapy for Palliation of Main Portal Vein Tumor Thrombosis27 April 2022 | Frontiers in Oncology, Vol. 12Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?5 July 2021 | Expert Opinion on Investigational Drugs, Vol. 31, No. 4Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?30 June 2021 | Expert Opinion on Investigational Drugs, Vol. 31, No. 4PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?30 August 2021 | Expert Opinion on Investigational Drugs, Vol. 31, No. 4Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?10 April 2022 | Expert Review of Gastroenterology & Hepatology, Vol. 16, No. 4Suppression of the transforming growth factor-β signaling pathway produces a synergistic effect of combination therapy with programmed death receptor 1 blockade and radiofrequency ablation against hepatic carcinoma in mice30 March 2022 | Bioengineered, Vol. 13, No. 4Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma18 March 2022 | Expert Review of Molecular Diagnostics, Vol. 22, No. 3Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola & Giovanni Brandi3 February 2022 | Future Oncology, Vol. 18, No. 8Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kitAnnals of Hepatology, Vol. 27, No. 2Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinomaAnnals of Hepatology, Vol. 27, No. 2Novel Gene Signatures as Prognostic Biomarkers for Predicting the Recurrence of Hepatocellular Carcinoma9 February 2022 | Cancers, Vol. 14, No. 4Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?15 May 2022 | Expert Review of Precision Medicine and Drug Development, Vol. 7, No. 1Overexpressed PAQR4 predicts poor overall survival and construction of a prognostic nomogram based on PAQR family for hepatocellular carcinomaMathematical Biosciences and Engineering, Vol. 19, No. 3A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institutionCancer Treatment and Research Communications, Vol. 30Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook1 March 2022 | Journal of Hepatocellular Carcinoma, Vol. Volume 9Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma1 April 2022 | International Journal of General Medicine, Vol. Volume 15All-Trans-Retinoic Acid Plus Oxaliplatin/Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis: A Multicenter Retrospective Study1 May 2022 | Cancer Management and Research, Vol. Volume 14Development of a prognostic gene signature for hepatocellular carcinomaCancer Treatment and Research Communications, Vol. 31Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapyCancer Treatment and Research Communications, Vol. 31Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials14 April 2022 | Cancer Control, Vol. 29Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?17 December 2021 | Frontiers in Oncology, Vol. 11Evolving therapeutic strategies for advanced hepatocellular carcinoma15 July 2021 | Expert Opinion on Pharmacotherapy, Vol. 22, No. 18Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma2 December 2021 | Frontiers in Immunology, Vol. 12Optimizing outcomes in HCC: Comment on "optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et al.Translational Oncology, Vol. 14, No. 12Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysisTranslational Oncology, Vol. 14, No. 12Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma26 November 2021 | Frontiers in Immunology, Vol. 12First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges31 August 2021 | Expert Review of Gastroenterology & Hepatology, Vol. 15, No. 11Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference studySiu Hing Lo, Rohini Sharma, Charlotte E Costentin, Daniel Aggio, Suki Shergill, Fabien Colaone, Victoria K Brennan, Vincenzo A Straccia, Ion Agirrezabal & Andrew J Lloyd27 July 2021 | Future Oncology, Vol. 17, No. 32Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma18 August 2021 | Expert Review of Gastroenterology & Hepatology, Vol. 15, No. 10Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy6 September 2021 | Frontiers in Oncology, Vol. 11Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody24 August 2021 | Frontiers in Immunology, Vol. 12Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockadeTranslational Oncology, Vol. 14, No. 8Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network12 July 2021 | Bioscience Reports, Vol. 41, No. 7Atezolizumab in advanced hepatocellular carcinoma: good things come to those who waitAlessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi6 April 2021 | Immunotherapy, Vol. 13, No. 8Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer9 March 2021 | Expert Opinion on Investigational Drugs, Vol. 30, No. 4First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!"Cancer Treatment and Research Communications, Vol. 27The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancerCancer Treatment and Research Communications, Vol. 27An Overview of the Genomic Characterization of Hepatocellular Carcinoma1 September 2021 | Journal of Hepatocellular Carcinoma, Vol. Volume 8An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma1 July 2021 | Journal of Hepatocellular Carcinoma, Vol. Volume 8Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads1 December 2021 | Cancer Management and Research, Vol. Volume 13 Vol. 17, No. 7 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 255 times History Received 26 September 2020 Accepted 26 October 2020 Published online 29 January 2021 Published in print March 2021 Information© 2021 Future Medicine LtdKeywordsatezolizumabbevacizumabHCChepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapyFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents, received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download